U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H15NO2S
Molecular Weight 273.3517
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MODAFINIL

SMILES

c1ccc(cc1)C(c2ccccc2)S(=O)CC(=N)O

InChI

InChIKey=YFGHCGITMMYXAQ-UHFFFAOYSA-N
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf | https://www.drugs.com/pro/armodafinil.html

Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to the dopamine transporter and inhibit dopamine reuptake. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

914371200000
Primary
PROVIGIL

Approved Use

Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Launch Date

914371200000
Primary
NUVIGIL

Approved Use

NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient.

Launch Date

1181865600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.4 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.5 μg/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13.4 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.8 μg/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 μg/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.1 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.4 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.2 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
4.1 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.9 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
136.1 μg × h/mL
250 mg 1 times / day multiple, oral
dose: 250 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
150.4 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
189.5 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23.4 μg × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
56.2 μg × h/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
142.9 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
146 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15.9 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
40.6 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.8 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
75.9 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ARMODAFINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
150 mg 1 times / day steady, oral
Recommended
dose: 150 mg 1 times / day
route: oral
experiment_type: steady
dose_type: Recommended
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/29734973
    unhealthy, 21 years
    population: unhealthy
    age: 21 years
    sex: F
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/29734973
    Disc. AE: Stevens-Johnson syndrome...
    AEs leading to
    discontinuation/dose reduction:​
    Stevens-Johnson syndrome (1 times / day)

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/29734973
    400 mg single, oral
    Highest studied dose
    dose: 400 mg
    route: oral
    experiment_type: single
    dose_type: Highest studied dose
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19133704
      healthy, 21–40 years
      population: healthy
      age: 21–40 years
      sex: M
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19133704
      150 mg 1 times / day steady, oral
      Recommended
      dose: 150 mg 1 times / day
      route: oral
      experiment_type: steady
      dose_type: Recommended
      co-adm with
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
        unhealthy
        population: unhealthy
        age:
        sex:
        food_status:
        n:
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
        Disc. AE: Headache...
        AEs leading to
        discontinuation/dose reduction:​
        Headache (1 times / day)

        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
        150 mg 1 times / day steady, oral
        Recommended
        dose: 150 mg 1 times / day
        route: oral
        experiment_type: steady
        dose_type: Recommended
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
          unhealthy
          population: unhealthy
          age:
          sex:
          food_status:
          n:
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
          Disc. AE: Rash, Angioneurotic edema...
          AEs leading to
          discontinuation/dose reduction:​
          Rash (1 times / day)
          Angioneurotic edema (1 times / day)
          Hyperhidrosis (1 times / day)
          Rash papular (1 times / day)

          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
          AEs

          AEs

          AESignificanceDosePopulation
          Angioneurotic edema 1%
          Disc. AE
          150 mg 1 times / day steady, oral
          Recommended
          dose: 150 mg 1 times / day
          route: oral
          experiment_type: steady
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
            unhealthy
            Headache 1%
            Disc. AE
            150 mg 1 times / day steady, oral
            Recommended
            dose: 150 mg 1 times / day
            route: oral
            experiment_type: steady
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
              unhealthy
              population:
              age:
              sex:
              food_status:
              n:
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
              Hyperhidrosis 1%
              Disc. AE
              150 mg 1 times / day steady, oral
              Recommended
              dose: 150 mg 1 times / day
              route: oral
              experiment_type: steady
              dose_type: Recommended
              co-adm with
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
                unhealthy
                Rash papular 1%
                Disc. AE
                150 mg 1 times / day steady, oral
                Recommended
                dose: 150 mg 1 times / day
                route: oral
                experiment_type: steady
                dose_type: Recommended
                co-adm with
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
                  unhealthy
                  Rash 2%
                  Disc. AE
                  150 mg 1 times / day steady, oral
                  Recommended
                  dose: 150 mg 1 times / day
                  route: oral
                  experiment_type: steady
                  dose_type: Recommended
                  co-adm with
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf
                    unhealthy
                    Stevens-Johnson syndrome 1 pts%
                    Disc. AE
                    150 mg 1 times / day steady, oral
                    Recommended
                    dose: 150 mg 1 times / day
                    route: oral
                    experiment_type: steady
                    dose_type: Recommended
                    co-adm with
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/29734973
                      unhealthy, 21 years
                      population:
                      age:
                      sex:
                      food_status:
                      n:
                      data_source:
                      https://pubmed.ncbi.nlm.nih.gov/29734973
                      PubMed

                      PubMed

                      TitleDatePubMed
                      Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice.
                      1995 Dec
                      Dopaminergic role in stimulant-induced wakefulness.
                      2001 Mar 1
                      Narcolepsy and psychopathology: is there an association?
                      2002 Jul
                      Acute behavioral and physiological effects of modafinil in drug abusers.
                      2002 Mar
                      Is psychosis exacerbated by modafinil?
                      2002 Mar
                      Modafinil for social phobia and amphetamine dependence.
                      2002 Nov
                      Temporal pattern of hippocampal high-frequency oscillations during sleep after stimulant-evoked waking.
                      2003
                      Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies.
                      2003 Apr
                      Modafinil in children with attention-deficit hyperactivity disorder.
                      2003 Aug
                      Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.
                      2003 Jun
                      Modafinil increases histamine release in the anterior hypothalamus of rats.
                      2003 Mar 20
                      Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.
                      2003 May 1
                      Narcolepsy drug could be approved for wider use.
                      2003 Oct 4
                      You'll lose sleep over this pill.
                      2003 Sep 29
                      Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.
                      2003 Sep-Oct
                      Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity.
                      2004 Aug
                      Modafinil treatment of excessive sedation associated with divalproex sodium.
                      2004 Jan
                      Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization.
                      2004 Nov 18
                      Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers.
                      2005
                      A double-blind, placebo-controlled trial of modafinil for cocaine dependence.
                      2005 Jan
                      [Effect of diazepam and modafinil on acute hepatic failure in mice].
                      2005 Jun
                      Prediction of genotoxicity of chemical compounds by statistical learning methods.
                      2005 Jun
                      Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
                      2006 Feb
                      Use of modafinil for the treatment of attention deficit/hyperactivity disorder.
                      2006 Oct
                      Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life.
                      2007
                      Psychostimulants and military operations.
                      2007 Apr
                      Acute chorea and hyperthermia after concurrent use of modafinil and tranylcypromine.
                      2007 Apr
                      Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
                      2007 Jul
                      Mechanisms of modafinil: A review of current research.
                      2007 Jun
                      Chest tightness and palpitations associated with modafinil and consumption of free glutamate.
                      2008 Apr
                      Modafinil: a review of neurochemical actions and effects on cognition.
                      2008 Jun
                      Smoked cocaine self-administration is decreased by modafinil.
                      2008 Mar
                      Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
                      2008 Oct
                      Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity.
                      2009 Aug
                      A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
                      2009 Feb
                      How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion.
                      2009 Jun
                      Modafinil treatment of amphetamine abuse in adult ADHD.
                      2009 Jun
                      Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
                      2009 May
                      Open-label pilot study of modafinil for methamphetamine dependence.
                      2009 Oct
                      Modafinil for the treatment of cocaine dependence.
                      2009 Sep 1
                      [Modafinil in psychiatric disorders: the promising state reconsidered].
                      2010
                      Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT.
                      2010 Aug
                      Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.
                      2010 Jun
                      Normalizing effects of modafinil on sleep in chronic cocaine users.
                      2010 Mar
                      Modafinil for bipolar depression with comorbid methamphetamine abuse.
                      2010 Mar-Apr
                      A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.
                      2010 May
                      A retrospective review of supratherapeutic modafinil exposures.
                      2010 Sep
                      Armodafinil in the treatment of sleep/wake disorders.
                      2010 Sep 7
                      Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
                      2015 May 18
                      Patents

                      Sample Use Guides

                      In Vivo Use Guide
                      Dosage in Narcolepsy and Obstructive Sleep Apnea (OSA)
                      Route of Administration: Oral
                      At high concentrations of modafinil (>/=100 uM), the mean activity of CYP2C9 in pooled human liver microsomes was decreased (up to 60%) relative to that in the solvent controls.
                      Name Type Language
                      MODAFINIL
                      EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
                      USAN   INN  
                      Official Name English
                      NSC-759110
                      Code English
                      CEP-1538
                      Code English
                      THN-102 COMPONENT MODAFINIL
                      Code English
                      CEP 1538
                      Code English
                      ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-
                      Systematic Name English
                      MODAFINIL [MART.]
                      Common Name English
                      DEP-1538
                      Code English
                      CRL 40476
                      Code English
                      NSC-751178
                      Code English
                      MODAFINIL [USP MONOGRAPH]
                      Common Name English
                      (+/-)-MODAFINIL
                      Common Name English
                      CRL-40476
                      Code English
                      THN102 COMPONENT MODAFINIL
                      Code English
                      MODAFINIL [USAN]
                      Common Name English
                      2-((DIPHENYLMETHYL)SULFINYL)ACETAMIDE
                      Systematic Name English
                      CRC-40476
                      Code English
                      MODIODAL
                      Brand Name English
                      MODAFINIL [JAN]
                      Common Name English
                      MODAFINIL [INN]
                      Common Name English
                      MODAFINIL [WHO-DD]
                      Common Name English
                      MODAFINIL CIV
                      USP-RS  
                      Common Name English
                      MODAFINIL [EP MONOGRAPH]
                      Common Name English
                      MODAFINIL [HSDB]
                      Common Name English
                      MODAPHONIL
                      Brand Name English
                      PROVIGIL
                      Brand Name English
                      MODAFINIL [MI]
                      Common Name English
                      MODAFINIL CIV [USP-RS]
                      Common Name English
                      MODAFINIL [VANDF]
                      Common Name English
                      MODAFINIL [ORANGE BOOK]
                      Common Name English
                      Classification Tree Code System Code
                      NCI_THESAURUS C47795
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      NDF-RT N0000175651
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      FDA ORPHAN DRUG 73793
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      FDA ORPHAN DRUG 536716
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      NDF-RT N0000175729
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      DEA NO. 1680
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      WHO-ATC N06BA07
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      NDF-RT N0000175769
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      WHO-VATC QN06BA07
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      LIVERTOX 649
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      Code System Code Type Description
                      INN
                      6055
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      DRUG BANK
                      DB00745
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      MERCK INDEX
                      M7584
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY Merck Index
                      USP_CATALOG
                      1445404
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY USP-RS
                      LACTMED
                      Modafinil
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      CAS
                      112111-49-6
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      SUPERSEDED
                      MESH
                      C048833
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      HSDB
                      7585
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      PUBCHEM
                      4236
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      FDA UNII
                      R3UK8X3U3D
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      EPA CompTox
                      68693-11-8
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      NCI_THESAURUS
                      C26661
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      IUPHAR
                      7555
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      CAS
                      68693-11-8
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      DRUG CENTRAL
                      1826
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      ChEMBL
                      CHEMBL1373
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      RXCUI
                      30125
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY RxNorm
                      EVMPD
                      SUB09026MIG
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY
                      WIKIPEDIA
                      MODAFINIL
                      Created by admin on Fri Jun 25 20:32:22 UTC 2021 , Edited by admin on Fri Jun 25 20:32:22 UTC 2021
                      PRIMARY